Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 273 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Follow-Up Questions
Who is the CEO of Camurus AB?
Mr. Fredrik Tiberg is the President of Camurus AB, joining the firm since 2002.
What is the price performance of CAMRF stock?
The current price of CAMRF is $68.85, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Camurus AB?
Camurus AB belongs to Pharmaceuticals industry and the sector is Health Care
What is Camurus AB market cap?
Camurus AB's current market cap is $4.0B
Is Camurus AB a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Camurus AB, including 4 strong buy, 7 buy, 2 hold, 0 sell, and 4 strong sell
